2012
PDCD6 is an independent predictor of progression free survival in epithelial ovarian cancer
Su D, Xu H, Feng J, Gao Y, Gu L, Ying L, Katsaros D, Yu H, Xu S, Qi M. PDCD6 is an independent predictor of progression free survival in epithelial ovarian cancer. Journal Of Translational Medicine 2012, 10: 31. PMID: 22369209, PMCID: PMC3305474, DOI: 10.1186/1479-5876-10-31.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overApoptosisApoptosis Regulatory ProteinsBlotting, WesternCalcium-Binding ProteinsCarcinoma, Ovarian EpithelialCell CycleCell Line, TumorCell ProliferationDisease-Free SurvivalFemaleGene Expression Regulation, NeoplasticGene Knockdown TechniquesGene SilencingGenetic VectorsHumansKaplan-Meier EstimateLentivirusMiddle AgedNeoplasm InvasivenessNeoplasm MetastasisNeoplasms, Glandular and EpithelialOvarian NeoplasmsRNA, MessengerRNA, Small InterferingStatistics, NonparametricTransfectionConceptsEpithelial ovarian cancerProgression-free survivalOvarian cancer progressionOvarian cancer cellsOvarian cancerFree survivalOverall survivalIndependent predictorsKaplan-Meier survival analysisEpithelial ovarian cancer tissuesMetastatic ovarian cancer cellsCancer progressionPDCD6 expressionResidual tumor sizeClinical pathological factorsEpithelial ovarian cancer correlatesCancer cellsOvarian cancer correlatesOvarian cancer tissuesHistologic typeClinical progressionTumor sizeDisease stageTumor gradeCancer correlates
2007
IGF-I in epithelial ovarian cancer and its role in disease progression
Brokaw J, Katsaros D, Wiley A, Lu L, Su D, Sochirca O, de la Longrais IA, Mayne S, Risch H, Yu H. IGF-I in epithelial ovarian cancer and its role in disease progression. Growth Factors 2007, 25: 346-354. PMID: 18236213, DOI: 10.1080/08977190701838402.Peer-Reviewed Original ResearchConceptsIGF-I transcriptsDisease progressionOvarian cancerTumor progressionEpithelial ovarian cancer patientsIGF-I mRNA expressionInsulin-like growth factorParacrine/autocrine regulationIGF-I activityEpithelial ovarian cancerIGF-I actionOvarian cancer patientsFresh tumor samplesIGF-I expressionIGF-I mRNAOvarian cancer progressionEnzyme-linked immunosorbentParacrine/autocrineTotal IGFFree IGFClinicopathologic featuresCA polymorphismCancer patientsReal-time PCRElevated risk
2006
Methylation of the insulin‐like growth factor binding protein‐3 gene and prognosis of epithelial ovarian cancer
WILEY A, KATSAROS D, FRACCHIOLI S, YU H. Methylation of the insulin‐like growth factor binding protein‐3 gene and prognosis of epithelial ovarian cancer. International Journal Of Gynecological Cancer 2006, 16: 210-218. PMID: 16445635, DOI: 10.1111/j.1525-1438.2006.00299.x.Peer-Reviewed Original ResearchMeSH KeywordsBiomarkers, TumorBiopsy, NeedleCarcinomaCohort StudiesDNA MethylationFemaleHumansImmunohistochemistryInsulin-Like Growth Factor Binding Protein 3Multivariate AnalysisNeoplasm StagingOvarian NeoplasmsOvariectomyProbabilityPrognosisProportional Hazards ModelsRetrospective StudiesRisk FactorsSensitivity and SpecificitySurvival RateConceptsIGFBP-3 promoter methylationInsulin-like growth factorIGFBP-3Disease progressionOvarian cancerGrowth factorPromoter methylationEarly-stage ovarian cancerEpithelial ovarian cancer patientsResidual tumor sizeEarly-stage diseaseIGFBP-3 expressionEpithelial ovarian cancerOvarian cancer patientsUseful prognostic markerOvarian cancer progressionIGFBP-3 promoterMethylation-specific polymerase chain reactionIGFBP-3 genePathologic variablesTumor sizeDisease stageCancer patientsPolymerase chain reactionPrognostic markerMethylation of the insulin-like growth factor binding protein-3 gene and prognosis of epithelial ovarian cancer
Wiley A, Katsaros D, Fracchioli S, Yu H. Methylation of the insulin-like growth factor binding protein-3 gene and prognosis of epithelial ovarian cancer. International Journal Of Gynecological Cancer 2006, 16: 210. DOI: 10.1136/ijgc-00009577-200601000-00034.Peer-Reviewed Original ResearchIGFBP-3 promoter methylationInsulin-like growth factorIGFBP-3Disease progressionOvarian cancerGrowth factorPromoter methylationEarly-stage ovarian cancerEpithelial ovarian cancer patientsResidual tumor sizeEarly-stage diseaseIGFBP-3 expressionEpithelial ovarian cancerOvarian cancer patientsUseful prognostic markerOvarian cancer progressionIGFBP-3 promoterMethylation-specific polymerase chain reactionIGFBP-3 genePathologic variablesTumor sizeDisease stageCancer patientsPolymerase chain reactionPrognostic marker
2005
Glutathione S-transferase polymorphisms and ovarian cancer treatment and survival
Beeghly A, Katsaros D, Chen H, Fracchioli S, Zhang Y, Massobrio M, Risch H, Jones B, Yu H. Glutathione S-transferase polymorphisms and ovarian cancer treatment and survival. Gynecologic Oncology 2005, 100: 330-337. PMID: 16199080, DOI: 10.1016/j.ygyno.2005.08.035.Peer-Reviewed Original ResearchConceptsOvarian cancer treatmentDisease progressionGSTP1 genotypesGST polymorphismsPrimary epithelial ovarian cancerCox proportional hazards regressionFunctional polymorphismsGSTP1 Ile/IleCancer treatmentGSTP1 Ile/ValGlutathione S-transferase polymorphismsGSTM1 null patientsPost-operative chemotherapySubgroup of patientsProportional hazards regressionEpithelial ovarian cancerOvarian cancer survivalEffect of chemotherapyOvarian cancer prognosisOvarian cancer progressionVal/ValIle/IleIle/ValOverall survivalTumor characteristics
2004
Methylation of tumor suppressor gene p16 and prognosis of epithelial ovarian cancer
Katsaros D, Cho W, Singal R, Fracchioli S, de la Longrais I, Arisio R, Massobrio M, Smith M, Zheng W, Glass J, Yu H. Methylation of tumor suppressor gene p16 and prognosis of epithelial ovarian cancer. Gynecologic Oncology 2004, 94: 685-692. PMID: 15350359, DOI: 10.1016/j.ygyno.2004.06.018.Peer-Reviewed Original ResearchConceptsEpithelial ovarian cancerOvarian cancer prognosisOvarian cancerP16 methylationMethylation-specific PCRCancer prognosisPrimary epithelial ovarian cancerResidual tumor sizePromoter methylationRegression survival analysisOvarian cancer progressionFresh frozen tumor tissueP16 promoter methylationFrozen tumor tissueAdvanced diseaseNegative patientsOverall survivalPatient agePositive patientsPathological variablesTumor sizeDisease stageHistological gradeAggressive tumorsDisease progression
2001
IGFBP-3 in epithelial ovarian carcinoma and its association with clinico-pathological features and patient survival
Katsaros D, Yu H, Levesque M, Danese S, Genta F, Richiardi G, Fracchioli S, Khosravi M, Diamandi A, Gordini G, Diamandis E, Massobrio M. IGFBP-3 in epithelial ovarian carcinoma and its association with clinico-pathological features and patient survival. European Journal Of Cancer 2001, 37: 478-485. PMID: 11267857, DOI: 10.1016/s0959-8049(00)00423-8.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBiomarkers, TumorDisease-Free SurvivalEnzyme-Linked Immunosorbent AssayFemaleFollow-Up StudiesHumansInsulin-Like Growth Factor Binding Protein 3Middle AgedNeoplasm ProteinsNeoplasm StagingNeoplasms, Glandular and EpithelialOvarian NeoplasmsPrognosisRisk FactorsConceptsIGFBP-3 levelsInsulin-like growth factorLower IGFBP-3 levelsEpithelial ovarian carcinomaIGFBP-3Overall survivalPatient survivalOvarian carcinomaGrowth factorUnfavourable prognostic featuresIGFBP-3 concentrationsClinico-pathological featuresEpithelial ovarian cancerPatients' overall survivalResponse of patientsOvarian cancer progressionAnti-apoptotic actionClinicopathological featuresPathological variablesPrognostic featuresResidual tumorDisease progressionOvarian cancerDisease prognosisAverage age